What is the appropriate levetiracetam (Keppra) dosage in mg per kilogram for treating epilepsy?

Levetiracetam (Keppra) Dosing for Epilepsy

For routine epilepsy management, start levetiracetam at 20 mg/kg/day divided twice daily in children (ages 4-16) and 1000 mg/day (500 mg BID) in adults, titrating to a target maintenance dose of 60 mg/kg/day (maximum 3000 mg/day) in children and 3000 mg/day in adults. 1

Maintenance Dosing by Age and Indication

Partial Onset Seizures

Pediatric Patients (Ages 4 to <16 years):

• Initial dose: 20 mg/kg/day in 2 divided doses (10 mg/kg BID) 1
• Titration: Increase every 2 weeks by increments of 20 mg/kg 1
• Target maintenance dose: 60 mg/kg/day (30 mg/kg BID) 1
• If 60 mg/kg/day is not tolerated, the dose may be reduced; mean effective dose in clinical trials was 52 mg/kg/day 1

Adults (≥16 years):

• Initial dose: 1000 mg/day (500 mg BID) 1
• Titration: Increase by 1000 mg/day every 2 weeks as needed 1
• Maximum recommended dose: 3000 mg/day 1
• Doses above 3000 mg/day provide no additional benefit 1

Primary Generalized Tonic-Clonic Seizures

Pediatric Patients (Ages 6 to <16 years):

• Initial dose: 20 mg/kg/day in 2 divided doses (10 mg/kg BID) 1
• Titration: Increase every 2 weeks by 20 mg/kg increments 1
• Target dose: 60 mg/kg/day (30 mg/kg BID) 1
• Doses lower than 60 mg/kg/day have not been adequately studied for efficacy 1

Adults (≥16 years):

• Initial dose: 1000 mg/day (500 mg BID) 1
• Target dose: 3000 mg/day 1

Myoclonic Seizures (Ages ≥12 years with Juvenile Myoclonic Epilepsy)

• Initial dose: 1000 mg/day (500 mg BID) 1
• Target dose: 3000 mg/day 1
• Doses lower than 3000 mg/day have not been studied 1

Status Epilepticus Dosing

For benzodiazepine-refractory status epilepticus, use levetiracetam 40-60 mg/kg IV (maximum 2500-4500 mg) as a single bolus, administered at up to 100 mg/min. 2

Acute Seizure Management Protocols

Non-Convulsive Status Epilepticus:

• Loading dose: 40 mg/kg IV (maximum 2500 mg) as bolus, in addition to maintenance dose 3
• Maintenance after resolution: 15 mg/kg IV every 12 hours (maximum 1500 mg) 3

Convulsive Status Epilepticus:

• Loading dose: 40 mg/kg IV (maximum 2500 mg) as bolus, in addition to maintenance dose 3
• Maintenance after resolution: 30 mg/kg IV every 12 hours, OR increase prophylaxis dose by 10 mg/kg (to 20 mg/kg) every 12 hours (maximum 1500 mg) 3

Evidence for Status Epilepticus Dosing

The American College of Emergency Physicians (ACEP) 2024 guidelines recommend 40-60 mg/kg IV (maximum 2500-4500 mg) as second-line therapy for benzodiazepine-refractory status epilepticus, with efficacy comparable to fosphenytoin and valproate 2. A prospective study of 82 patients with refractory status epilepticus found 73% seizure cessation with levetiracetam 30 mg/kg IV 3. Multiple Class III studies support doses of 20-30 mg/kg for status epilepticus, with efficacy ranging from 44% to 73% 3.

Important caveat: A 2024 retrospective study found no difference in seizure termination rates between low (≤20 mg/kg), medium (21-39 mg/kg), and high (≥40 mg/kg) doses, but the high-dose group had significantly higher intubation rates (45.8% vs 26.8-28.2%) 4. This suggests that while higher doses are guideline-recommended, clinicians should monitor closely for respiratory depression requiring intubation.

High-Dose Considerations

Some children with refractory epilepsy may benefit from doses exceeding the standard 60 mg/kg/day maximum. 5, 6

• A retrospective study of 32 children found that doses up to 275 mg/kg/day (median 146 mg/kg/day) were tolerated, with 44% achieving >50% seizure reduction and 16% achieving seizure freedom 5
• For acute seizure exacerbations, IV doses averaging 228 mg/kg/day (range 150-300 mg/kg/day) resolved acute repetitive seizures in 8 of 9 children 6
• Adverse effects at high doses were primarily behavioral and occurred in only 12% of patients 5
• Clinical pearl: If a child partially responds to standard doses (60 mg/kg/day), consider escalating above this threshold rather than switching agents 5

Dosing in Special Populations

Renal Impairment (Adults)

Levetiracetam dosing must be adjusted based on creatinine clearance 1:

Creatinine Clearance	Dose	Frequency
>80 mL/min (Normal)	500-1500 mg	Every 12 hours
50-80 mL/min (Mild)	500-1000 mg	Every 12 hours
30-50 mL/min (Moderate)	250-750 mg	Every 12 hours
<30 mL/min (Severe)	250-500 mg	Every 12 hours
ESRD on dialysis	500-1000 mg	Every 24 hours*

*Following dialysis, administer a 250-500 mg supplemental dose 1

Absence Epilepsy

Levetiracetam is not recommended as first-line therapy for absence epilepsy. 7

• A retrospective study of 72 children with absence epilepsy found that levetiracetam was discontinued in 74% due to incomplete seizure control (59%) or intolerable side effects (41%) 7
• Only 26% of children became seizure-free with levetiracetam 7
• When effective, lower doses (mean 29 mg/kg/day) were sufficient; lack of seizure control requiring continued dose escalation should prompt early medication transition 7

Safety and Monitoring

Levetiracetam does not require routine therapeutic drug monitoring, as serum levels do not correlate with seizure control or adverse events. 2

• Instead, monitor complete blood count periodically 2
• Measure serum levels only in cases of suspected toxicity, non-adherence, or drug interactions 2
• Most common adverse effects are mild nausea and rash 2
• Levetiracetam has significantly lower rates of hypotension (0.7%) compared to fosphenytoin (3.2%) 2
• Lower intubation requirement (20%) versus fosphenytoin (26.4%) 2
• No hepatic monitoring required, unlike phenytoin and valproate 2

Geriatric Considerations

Older adults frequently experience somnolence, dizziness, and mental confusion; initiate at low doses and titrate slowly to mitigate neuropsychiatric side effects 2

Drug Interactions

Caution with concomitant carbamazepine: A 2025 case-control study found that co-administration of levetiracetam with carbamazepine increased the odds of carbamazepine toxicity by 16.65-fold (95% CI: 3.52-78.70) 8. When the LEV:CBZ dose ratio exceeds 1.86, the risk of toxic carbamazepine levels increases significantly 8. Monitor for carbamazepine toxicity symptoms when combining these agents.

Administration Considerations

• Levetiracetam can be administered with or without food 1
• For children ≤20 kg, use oral solution 1
• For children >20 kg, either tablets or oral solution may be used 1
• IV formulation can be administered rapidly at up to 100 mg/min 2
• Oral solution concentration is 100 mg/mL; use a calibrated measuring device, not household spoons 1